TB-500 and thymosin beta-4

The protein fragment called TB-500, the research often wrongly credited to it, and the open questions about its use in people and about product quality.

Bottom line

TB-500 is a specific piece of protein, seven amino acids long, linked to the sequence LKKTETQ. (Amino acids are the building blocks of proteins.) It carries an acetyl group, a small chemical tag. The FDA (the U.S. government agency that approves medicines) found no studies in people that used TB-500, given in any way. It also found no data on how much of it gets into people's bodies. Studies of full-length thymosin beta-4, or of a fragment without the acetyl tag, cannot show that TB-500 helps or is safe.389

Evidence in people
No useful studies found of TB-500 given to people
Approval status
TB-500 is not FDA-approved. The FDA reviewed two forms of it: the free base and the acetate. Neither form is part of any FDA-approved drug. FDA staff assessed both forms in July 2026. They concluded that the evidence weighed against placing either one on the 503A Bulks List (the FDA's list of ingredients pharmacies may use to make custom medicines).312
Biggest unknown
Papers on thymosin beta-4 are often cited as if they had tested TB-500 in people. So are papers on cells, on animals, or on an LKKTETQ fragment without the acetyl tag. None of them settled whether a defined TB-500 product works in people. None settled how much of it reaches the body or whether the immune system reacts against it. None settled how safe it is over the longer term.389

Where research exists

Filled markers show which stages of research this guide covers. They don't rate effectiveness, safety, or study quality.

  • Health results in peopleNo useful studies found
  • Blood tests and body measurements in peopleNo useful studies found
  • Animal studiesCovered in this guide
  • Lab studies in cellsCovered in this guide
  • Untested idea or marketing claimCovered in this guide

What TB-500 is

The FDA's 2026 assessment defines TB-500 as a lab-made piece of protein, seven amino acids long. It contains the sequence LKKTETQ, which matches part of thymosin beta-4. An acetyl group is attached at the start of the chain (the N-terminal end). This acetyl tag is part of what defines the substance the FDA evaluated.3

Full-length thymosin beta-4 is a peptide 43 amino acids long. It is a different substance from TB-500. Even so, websites and some discussions use the two names as if they meant the same thing.39

TB-500 free base and TB-500 acetate are separate active drug ingredients. The FDA found inconsistent names, ID codes, chemical formulas, and certificate information. This was true in the nomination and in products on the market. So the short name alone may not be enough to identify the material.32

Calling TB-500 a “synthetic version” of the body's thymosin beta-4 hides a major difference in structure. Evidence about the full parent protein applies to the fragment only if direct evidence links the two.3

Why people link TB-500 to wound healing

The LKKTETQ sequence sits in a part of thymosin beta-4 that binds to a protein called actin. Because of this, the same ideas about how it might work keep coming up in research papers. These are cell movement, the growth of new blood vessels, responses in the material that surrounds cells, and wound repair.38

The FDA found TB-500 widely promoted for injury recovery, wound repair, inflammation, flexibility, and mobility. It was also promoted for scarring, collagen, and other outcomes. These claims go beyond the direct evidence for TB-500 in people. The FDA found no such evidence.3

Sharing a core amino-acid sequence is not enough to show that two molecules act the same way in the body. Adding the acetyl tag can change several properties in ways that can't be undone. These are its electric charge, how strongly it repels water, and its size. They also include how it folds, how long it lasts, and how it binds to other molecules.3

Studies in people

The FDA found no studies in people that used TB-500, given in any way. It found no data on how much of it gets into people's bodies. It found no published case reports (reports on single patients) either. It also found no report in the medical literature of patients given TB-500 for wound healing or another condition.3

The wound studies in people that are sometimes cited for TB-500 gave patients full-length thymosin beta-4. That is a different substance. So those results cannot show that TB-500 works or is safe.93

The FDA found no studies in people of how the body absorbs, spreads, and clears TB-500. It found none on what TB-500 does in the body either. Some animal studies measured how much reached the body and what it broke down into. Those findings cannot tell us how a person's response changes with the amount in their body. They also cannot tell us the dose range that helps patients without harming them.3

The evidence does not support a claim that TB-500 improves wound healing in people. It also does not support a precise estimate of its risks. TB-500's effects in people have not been shown, and thymosin beta-4 research cannot fill that gap.39

Animal and cell studies, by substance

A 2003 study reported wound-repair findings in diabetic and old mice. It used full-length thymosin beta-4 and an LKKTETQ peptide without the acetyl tag. It was an animal study. The FDA stressed that how the untagged fragment acts in the body cannot be applied directly to TB-500, which has the tag.83

The FDA found a lab study in which a layer of cells was scratched to mimic a wound. Under the conditions reported, TB-500 free base showed no wound-healing activity. One of its breakdown products did show some sign of activity. A breakdown product's effect in cells does not show what TB-500 itself does in a whole living body or in a patient.3

The FDA found no animal or lab studies testing TB-500 free base or TB-500 acetate for harm (toxicology studies). It also found that animal and lab studies of how TB-500 acts were not enough to support a wound-healing use. Basic safety questions are still open, even before asking whether it works in people.3

Check the details of every cited finding. Look at the exact molecule and whether it carries the acetyl tag. Look at the salt form, how it was given, and the product's makeup (its formulation). Look at the species studied and the result measured. If any of these change, the evidence may no longer support the same claim.37

Safety

No study was found in which people received TB-500. So it is unknown how often harms happen and how serious they are. That includes reactions across the whole body, interactions with other drugs, and harm to organs. It also includes effects on reproduction or a developing baby, and longer-term harms.3

The nomination had injectable products in mind. For any injected product, several things directly affect safety. These include its identity and strength, whether it is sterile (free of germs), and control of bacterial toxins (endotoxin). They also include stray particles and contamination with germs.3

The FDA flagged a possible concern that the immune system could react against injected TB-500. Clumping of the peptide and impurities related to it may make that concern greater. No study in people was found that looked at immune reactions to TB-500 or at its clumping.36

The FDA found two safety-monitoring reports about products that blended TB-500 with BPC-157. Those reports contained no safety assessments. Reports like these are few and are sent in voluntarily. Other factors could also explain what they describe. Such reports cannot show cause and effect, and they cannot offer reassurance.3

The FDA found important gaps in how both forms had been described and tested. These included missing or incomplete checks for impurities, clumps, germs, and bacterial endotoxin. A product name cannot make up for that missing quality data.34

What FDA evaluated in 2026

The TB-500 nomination was withdrawn. It also had inconsistent information about the free-base and acetate forms. The FDA chose to evaluate both forms on its own initiative.3

The July 2026 review looked at whether TB-500 could go on the 503A Bulks List for a proposed wound-healing use. It was a review of compounding policy (the rules for pharmacies that make custom medicines). No application for FDA approval of a finished drug was involved.32

FDA staff concluded that several things weighed against placing both forms on the 503A Bulks List. One was how their physical and chemical makeup had been described and tested. Another was their unclear history of use in compounding. The others were the lack of evidence that they work and the absence of safety information in people.3

The Pharmacy Compounding Advisory Committee (PCAC) is a panel that advises the FDA. The FDA does not have to follow its advice. Its process approves nothing. A recommendation against putting TB-500 on the list does not say it is banned in every legal or research setting.51

The FDA's current page on compounding risks includes the thymosin beta-4 fragment known as TB-500. It points to concerns about immune reactions, clumping, impurities, and missing data in people. It sums up the risk as a regulator sees it. It does not put a number on the risk in people.4

Questions to ask about a TB-500 claim

What did the cited study test? Was it full-length thymosin beta-4, LKKTETQ without the acetyl tag, or TB-500 with the tag? Was it a breakdown product, the free base, or the acetate? Does the claim name that exact substance?389

Was TB-500 given to people in a controlled study (one that compares people who get it with a similar group who don't)? Did that study measure healing, pain, function, or another result patients care about? Or is a claim about people being drawn from cells, mice, or another molecule?3

For the finished product, what independent evidence covers its identity, strength, and sterility? What covers bacterial endotoxin, particles, impurities, and clumping? What covers the risk of immune reactions and the tracking of side effects?36

How the compounding review works

The July 2026 meeting dealt with a process for compounding that is set by law. This process runs separately from FDA drug approval. It has four steps.

  1. A substance is nominated
    A nomination asks the FDA to consider a raw drug ingredient (a bulk drug substance). It asks whether the ingredient may qualify for a compounding list set by law. Drug approval needs a separate application.
  2. FDA staff assess the record
    The FDA looks at what is known about the substance's makeup, past use, effectiveness, and safety. It does this for the use named in the nomination. It then writes a public briefing memo.
  3. PCAC gives advice the FDA doesn't have to follow
    The Pharmacy Compounding Advisory Committee discusses the questions and advises the FDA. Its recommendation is only advice. It approves nothing.
  4. The FDA considers final agency action
    The FDA weighs the committee's input and finishes its reviews. Only after that does it take any final agency action (its formal, final decision). A meeting or a staff position alone never counts as that final step.

A staff memo is an assessment by FDA staff. An advisory committee recommendation is advice. Neither one is an FDA decision.

References

  1. 1
    July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration · 2026-07-23 · FDA document

    The meeting record lists the substances proposed for the list and the uses discussed. The committee's votes are advice only. They are not an FDA approval or a final FDA decision.

  2. 2
    2026 PCAC Voting QuestionsU.S. Food and Drug Administration · 2026-07-23 · FDA document

    The questions ask whether the free-base and acetate forms should be placed on the 503A bulks list. Drug approval was outside their scope.

  3. 3
    TB-500: Pharmacy Compounding Advisory Committee Briefing DocumentU.S. Food and Drug Administration · 2026-07-23 · FDA document

    The FDA reviewed TB-500 as a short lab-made fragment (acetylated LKKTETQ) and found no studies or data from people given it. Evidence for the full natural protein, thymosin beta-4, applies only to that protein.

  4. 4
    Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration · 2026-07-23 · FDA document

    FDA's current compounding-risk summary includes BPC-157, KPV, MOTS-c, and the thymosin beta-4 fragment known as TB-500. The listing flags risks and stops well short of a complete safety profile.

  5. 5
    Advisory Committees: Critical to the FDA's Product Review ProcessU.S. Food and Drug Administration · 2018-01-04 · FDA document

    The FDA explains that the committee only gives advice, which the FDA does not have to follow, and that the FDA makes the final decision.

  6. 6
    Immunogenicity Risk of Peptide Drug Products: Scientific and Regulatory ConsiderationsU.S. Food and Drug Administration · 2024-09-11 · FDA document

    How a peptide is made up and given, clumping, and impurities can all change the risk of immune reactions. This is a general rule. Each product still has to be tested on its own.

  7. 7
    Clinical Pharmacology Considerations for Peptide Drug ProductsU.S. Food and Drug Administration · 2023-12-01 · FDA document

    This is draft advice from the FDA, which drug makers do not have to follow, on developing peptide drugs. It lists questions each product must answer: how the body absorbs and clears it, use in people with liver or kidney problems, drug interactions, effects on heart rhythm, and immune reactions.

  8. 8
    Thymosin Beta 4 and a Synthetic Peptide Containing Its Actin-Binding Domain Promote Dermal Wound Repair in Diabetic and Aged MiceWound Repair and Regeneration (PubMed record) · 2003-01-01 · Animal or lab study

    A preclinical study in cells and mice. Check the exact identity of its synthetic fragment before relating it to acetylated TB-500.

  9. 9
    The Effect of Thymosin Treatment of Venous UlcersAnnals of the New York Academy of Sciences (PubMed record) · 2010-04-01 · Study in people

    This trial tested the full natural protein, thymosin beta-4, which has 43 amino acids. TB-500 is a piece only seven amino acids long, so the trial can't show whether TB-500 works or is safe.

Evidence last checked August 22, 2026.

Educational use only. This guide does not diagnose, prescribe, recommend a product or replace care from a licensed clinician.